Strides Pharma Science Limited — Updates, 30-04-2025: Press Release

Strides Pharma Science Limited's wholly-owned subsidiary has received USFDA approval for Celecoxib Capsules (100 mg, 200 mg, 400 mg), expanding its anti-inflammatory portfolio. This bioequivalent product addresses a market size of about US$ 116 million, positioning Strides to enhance its presence in the pain management sector. Production will take place at the Puducherry facility, underscoring the company's commitment to offering effective and affordable treatment options for various inflammatory conditions.